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Background: The main aim of this study is to estimate the rate of false negative and true IC on the Program for
the Early Detection of Breast Cancer (PEDBC) run by the Girona Health Region (GHR) and compare the clinicopathological
characteristics of these tumors with those detected within the same program.
Methods: A retrospective cohort study including all women participating on the Girona PEDBC between 2000 and
2006, with negative mammography screening. The IC included are those detected between the first and second round
of screening and between the second and third round.
Results: We identified a total of 43 IC, representing an incidence rate of 0.70 cases per 1,000 screened women. Of the
43 probable IC, we were able to classify a total of 22 (51.2%) cases. Of these 22 cases, 54.5% were classified as true
interval tumors, 13.6% false negatives, 18.2% occult tumors and the remaining 13.6% minimal sign.
We found significant differences in some clinicopathological characteristics of the IC comparing with the tumors
detected within the program during the same period.
Conclusions: The IC rate for the PEDBC is within the expected parameters, with a high proportion of cases of true
interval cancers (54.5%) and a low proportion of false negatives (13.6%). The results show that the proportional
incidence of IC is within the limits set by European Guidelines. Furthermore, it has been confirmed that IC display more
aggressive clinicopathological characteristics than screening breast cancers.
Keywords: Interval cancer rate, Propotional incidence, Clinicopathological characteristicsBackground
Breast cancer is the most common cancer in Spanish
women. In Spain, approximately 16,000 cases are diag-
nosed and 6,000 deaths occur annually due to this
disease [1]. Breast cancer mortality in Western countries
has followed a downward trend since the early 90s [2]. It
has been estimated that the use of screening mammog-
raphy and adjuvant treatments for breast cancer have
had a similar impact on improving survival [3].
The natural history of breast cancer, with its long
preclinical phase, favors the possibility of early detection
through mammography screening. The introduction of* Correspondence: gemma.renart@udg.edu
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article, unless otherwise stated.screening programs for breast cancer have reduced mor-
tality from this neoplasm between 10% and 35% [3-5],
varying by age, years of follow-up, number of women
screened and frequency of mammography. However,
certain adverse effects of mammography screening have
to be considered. The most important are interval can-
cer and false negative breast cancers. Analysis of inteval
cancers (IC) is critical in determining screening sensiti-
vity and represents an objective measure of the quality
of the screening program in the sense that increased
detection of tumors on the program must lead to a lower
incidence of IC. So the interval cancer rate is a key com-
ponent of quality control for programs using both conven-
tional and digital mammography.
The IC, as defined by the European Guidelines for
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a woman who has undergone screening, with or without
additional assessment, and the result was negative for
malignancy. The diagnosis must be made before the next
invitation onto the program or within a period equal to
the screening interval if the woman has reached the age
limit for participation. Published studies [7-9] show that
IC and screen-detected tumors have different clinico-
pathologic characteristics, IC being more aggressive. IC
tends to have a worse prognosis, with a higher proportion
of large tumors, lymph node involvement, advanced stages,
high histologic grade and negative hormone receptors.
However, IC tumors are a heterogeneous group of
tumors. It can be classificate into four categories by the
retrospective review of both screening and diagnostic
mammograms: true interval cancers, false-negative can-
cers, minimal-signs and occult tumors. True interval can-
cers are those that showed normal or benign features in
the previous screening mammogram; false-negative can-
cers are detected when signs suspicious for malignancy are
retrospectively seen on a mammogram; minimal-signs are
cancers showing detectable but non-specific signs at the
latest screening; and occult tumors are those that present
clinical signs of the disease despite a lack of mammo-
graphic abnormalities either at screening or at diagnosis.
Information on IC and the false-negative, both related
to women and to program, is useful for assessing and
adapting screening strategies, for evaluating the work of
radiologistsand thereby reducing the proportion of false
negatives, achieving higher screening sensitivity.
Although IC are inevitable in a screening program, it
is recommended that their frequency should kept very
small, since a high proportion would decrease screening
effectiveness. In Europe, several studies have assessed IC
within the framework of screening programs [10-16]. In
general, reported incidents do not exceed the limits
recommended by European Guidelines (incidence <0.30
the first year and <0.50 the second).
The main aim of this study is to estimate the rate of
false negative and true IC on the Program for the Early
Detection of Breast Cancer (PEDBC) and compare the
clinicopathological characteristics of these tumors with
those detected within program.
Methods
Design and study population
We performed a retrospective study including all women
screened in the Girona PEDBC between 1 January 2000
and 31 December 2006, and followed up until June 2009
with a negative mammography screening; 32,783 women.
The study period involves the IC detected between the
first and second round of screening and between the
second and third round. We included both invasive
(ICD-O-3: C50.0-C50.9) and in situ tumors (ICD-O-3:D050-D059) [17] and for simultaneous bilateral tumors,
the most aggressive of the two was considered.
All women resident in Girona Health Region aged
between 50 and 69 years are actively invited to partici-
pate in the propulation-based screening program every
2 years. The Girona Health Region’s (GHR) PEDBC was
introduced with a pilot testing in 1999 and was extended
throughout the GHR in 2001. Following the European
guideline recommendations [6], the test performed is
the double projection mammography and double read-
ing every two years. During the study period, the PEDBC
consisted of six radiological units covering aproximately
20% of the female population in 2006 and the participa-
tion rate was around 64%. Only one of these units
switched to digital mammography in 2004.
The Girona Cancer Registry (GCR) is a population-
based registry that collects information on all cases of
breast and female genital cancer diagnosed in patients
living in the province of Girona since 1980, expanded to
all tumor sites since 1994. According to the 2007 census,
the GCR covered a population of 339,660 women, repre-
senting 9.4% of the Catalan population. Additionally,
during the period 2007-09, the quality data indicators of
the GCRwere as follow: proportion of death certificate
only (DCO) of 2.7%, the histological verification (VH) of
91.2% and a mortality-incidence ratio (M/I) of 30.2%.
Study data were collected using a protocol approved by
the ethics committes of the University Hospital “Doctor
Josep Trueta” (CEIC-Hospital Josep Trueta), Girona.
Specific patient consent was not requiered because we
used retrospective data from screening participants who
had previously signed information release documents.
To identify probable IC, the PEDBC and GCR data-
bases have been cross-referenced. From these databases,
information has been collected from all women who par-
ticipated at least once on the program between 01/01/
2000 and 31/12/2006. However, in order to ensure follow-
up for all the women screened within the study period,
the GCR has provided population data for women with
breast tumors between 01/01/2000 and 30/06/2009.
After identifying probable cases of IC, the last mam-
mography screening and diagnostic mammography for
breast cancer was recovered for each case. A panel of
expert radiologists who regularly interpret mammo-
grams in the programme, classified the IC into true in-
tervals, false negatives, occult tumors and minimal signs
following the agreed protocol. It consisted on reviewing
both screening and diagnostic mammograms through in-
dependent double reading with arbitration. First, the ra-
diologists reviewed the screening mammograms without
seeing the diagnostic mammogram and classified into
positive (abnormality clearly visible and warrants assess-
ment), negative (normal mammogram), and minimal-
signs (subtle abnormality, not necessarily regarded as
Table 1 IC and PDPCM cancer incidence rate and IC
classification
N (‰) N (%)
Screening tumors [n (rate)] 299 (4.9)
Interval tumors [n (rate)] 43 (0.70)
Classified 22 (51.2)
True interval 12 (54.5)
False Negative 3 (13.6)
Occult Tumors 4 (18.2)
Minimal Signs 3 (13.6)
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reviewed together the diagnostic and screening mammo-
grams and classified into true interval cancers, false nega-
tives, minimal-signs cancers and occult tumors.
In turn, tumors detected by the PEDBC during the
study period have been identified. The following clinico-
pathological characteristics of screening tumors and
interval cancers were collected: age, stage (0-IV), tumor
size (≤9, 10-14, 15-19, 20-29, 30-49, ≥50 cm), number of
positive lymph nodes (none, 1-3, >3), histological grade
(poor, moderate, good), histology (invasive, in situ) hor-
mone receptor status (estrogen and progesterone recep-
tors), HER2 (human epidermal growth factor receptor
2) and molecular subtype (luminal A, luminal B, HER2-
overexpressed, triple negative) [18].
Analysis
The IC rate has been estimated as the number of tumors
diagnosed in a defined time period since the last nega-
tive screening examination for every 1,000 women with
negative mammography screenings. Confidence intervals
for the incidence rates of IC have been estimed assum-
ing a Poisson distribution.
Proportional incidence was estimated as the ratio of the
observed incidence of IC compared to the baseline inci-
dence expected in the absence of screening. The baseline
incidence rates were estimated using the incidence in the
50-59 and 60-69 years old age groups in the period before
screening, 1980-1989. A generalized linear model with
poisson distribution was used to estimate and projecte on
to the following years to obtain the incidences rates per
10,000 women. In the 50-59 and 60-69 years old age
groups, respectively, these were 13.77 and 22.2 for first
round, and 13.93 and 22.82 for the second.
We also calculated the sensitivity of the screening test,
which, according to the European Guidelines definition,
is the ability to identify a case during its detectable
phase, it being advisable to estimate it as the number of
cases detected by screening from the total number of
tumors detected in screened women (tumors detected
by the PEDBC and IC).
These indicators were stratified by age group (50-59
and 60-69), type of screening (initial and subsequent),
round number on the program and time elapsed
between last mammography screening and diagnosis
(less than 12 months, between 12-24 months). To com-
pare clinical characteristics between cases detected by
the screening program and the IC, the Chi-squared sta-
tistical test was used. The statistical analysis was per-
formed using version 19.0 of the SPSS.
Results
Table 1 shows the incidence rate for the IC and tumors
detected on the program during the study period, as wellas the classification of these probable IC. We identified a
total of 43 IC, representing an incidence rate of 0.70
cases per 1,000 screened women. During the same
period, 299 tumors were detected on the PEDBC, repre-
senting a detection rate of 4.9 tumors per 1,000 screened
women.
Of the 43 probable IC, we were able to classify a total
of 22 (51.2%) cases. Of these 22 cases, 54.5% were classi-
fied as true interval tumors, 13.6% false negatives, 18.2%
occult tumors and the remaining 13.6% minimal sign.
Table 2 shows the incidence rate of the IC according
to age group, screening type and program round. Of the
43 IC detected, 30 (69.8%) occurred in women aged 50
to 59 and 13 (30.2%) in women aged 60 to 69. Further-
more, 48.8% of all IC found were detected in the first
round and 65.1% at the initial screening. This table also
shows the sensitivity of the screening test. In all cases,
the sensitivity of the program (number of cases detected
by screening of the total number of tumors found in
women screened) lies between 83% and 93%.
When stratified according to time elapsed between
completion of the mammography screening and the
diagnostic mammography, we observe that of the initial
43 IC, 10 (23.3%) were detected up to 12 months after
the screening mammography and the remaining 33
(76.7%) after this time period (Table 3). Incidence and the
proportional incidence rate separated by time elapsed be-
tween mammography screening and diagnosis are also
shown and stratified similar to in Table 2. During the first
year after the screening mammography, the incidence rate
is found to be between 0.00 to 5.44 tumors per 10,000
women screened, and the proportional incidence between
0.00% and 23.84%. For IC detected during the second year
after the screening mammography, the incidence rate is
found to be between 2.88 and 10.89 tumors per 10,000
women screened and the proportional incidence between
12.97% and 47.72%.
Finally, Table 4 shows a comparison of the clinicopath-
ological characteristics of the IC with the tumors detected
within the program. We found significant differences in
the stage, tumor size, the number of positive nodes,
Table 2 Incidence rate by age group, screening type in Round 1 and Round 2
Women screened N Interval tumors N Ratio/10000 (95% IC poisson) Sensitivity (%)
50-59 initial
Round 1 20221 17 8.41 (8.37-8.45) 104/121 (85.95)
Round 2 7675 4 5.21 (5.11-5.26) 36/40 (90.0)
50-59 succesive
Round 2 14811 9 6.08 (6.04-6.12) 47/56 (83.93)
60-69 initial
Round 1 6953 4 5.75 (5.69-5.81) 53/57 (92.98)
Round 2 1837 3 16.33 (16.15-16.51) 17/20 (85.00)
60-69 successive
Round 2 9449 6 6.35 (6.30-6.40) 42/48 (87.50)
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present a higher proportion of tumors at an advanced
stage (14.0% vs. 0.9%), a larger size (5.4% vs. 2.3%), a larger
number of positive lymph nodes (13.5% vs. 7.7%), a higher
histological grade (37.9% vs. 23.1%) and a higher propor-
tion of cases with negative progesterone receptors (50.0%
vs. 26.9%) than tumors detected within the program itself.
Although not statistically significant, we detected a higher
proportion of triple negative tumors (16.2% vs. 7.5%) and
a lower frequency of luminal A (56.8% vs. 69.9%) in the IC
than in those from screening.
Discussion
In our study, we found an IC rate at line with the European
guidlines recommendation [6] and lower than the results
reported in other studies [15,19,20], with a high propor-
tion of cases of true interval cancers (54.5%) and a low
proportion of false negatives (13.6%).
Some studies evaluating interval cancers and following
the recommendations of the European guidelines have












Round 1 4 1.98 (1.96-2.00) 14.38
Round 2 1 1.30 (1.28-1.33) 9.33
50-59 succ
Round 2 2 1.35 (1.33-1.37) 9.69
60-69 init
Round 1 2 2.88 (2.84-2.92) 12.97
Round 2 1 5.44 (5.34-5.55) 23.84
60-69 succ 0 0.00 (0.00-0.00) 0.00
Round 2are false negative [7,13,21], and fewer than 20% are
occult tumors and minimal-signs cancers [15,21]. In fact,
the false negative is an avoidable interval cancer, as these
are tumors that are visible on the mammography but
not diagnosed by screening either due to misinterpre-
tation or technical error, and this type of cancer is there-
fore one that should be found in smaller proportions.
Our results are similar to those previously reported by
other screening programs (Table 5).
As a possible explanatory cause of the low proportion
of false negative could be the high immediate recall rate.
The immediate recall rate for the Girona program was
16.2% for the first round and 11.9% for the second, which
are higher than those recommended in the European
guidelines (≤5%) [6]. However, we found that programs
with similar proportions of false negative and true interval
cancer have a high immediate recall rate too [7,15,19,20,
22-24]. It is certain that an excessively low rate of immedi-
ate recall can significantly decrease the sensitivity of
screening. There is a clear compromise between the
percentage of seconds calls, detections rates and thece, screening type and time in Round 1 and Round 2










13 6.43 (6.39-6.46) 46.69
3 3.91 (3.86-3.95) 28.07
7 4.73 (4.69-4.76) 33.96
2 2.88 (2.84-2.92) 12.97
2 10.89 (10.74- 11.03) 47.72
6 27.83
6.35 (0.61-0.65)
Table 4 Initial characteristics of interval tumors and
tumors detected within PEDBC
Characteristics Interval tumors
N (%) (n = 43)
Screening tumors
N (%) (n = 299)
Age
50-59 30 (69.8) 187 (62.5)
60-69 13 (30.2) 112 (37.5)
Total 43 (100.0) 299 (100.0)
Stage**
0 4 (9.5) 35 (15.6)
I 10 (23.3) 111 (50.0)
II 16 (37.2) 59 (26.3)
III 6 (14.0) 14 (6.3)
IV 6 (14.0) 2 (0.9)
Total 42 (100.0) 224 (100.0)
Tumor size (cm)**
≤9 3 (8.1) 60 (27.3)
10-14 6 (16.2) 55 (25.0)
15-19 6 (16.2) 42 (19.1)
20-29 12 (32.4) 44 (20.0)
30-49 8 (21.6) 14 (6.4)
≥50 2 (5.4) 5 (2.3)
Total 37 (100.0) 220 (100.0)
Lymph nodes**
0 20 (54.1) 150 (71.8)
1-3 12 (32.4) 35 (16.7)
>3 5 (13.5) 16 (7.7)
Total 37 (100.0) 209 (100.0)
Histological grade**
Good 1 (3.4) 32 (21..8)
Moderate 17 (58.6) 81 (55.1)
Poor 11 (37.9) 34 (23.1)
Total 29 (100.0) 147 (100.0)
Histology
Invasive 38 (90.5) 196 (86.0)
In situ 4 (9.5) 32 (14.0)
Total 42 (100.0) 228 (100.0)
Estrogen receptor
Positive 30 (75.0) 180 (83.3)
Negative 10 (25.0) 36 (16.7)
Total 40 (100.0) 216 (100.0)
Progesterone receptor**
Positive 20 (50.0) 158 (73.1)
Negative 20 (50.0) 58 (26.9)
Total 40 (100.0) 216 (100.0)
Table 4 Initial characteristics of interval tumors and
tumors detected within PEDBC (Continued)
HER2
Positive 10 (27.0) 39 (22.5)
Negative 27 (73.0) 134 (77.5)
Total 37 (100.0) 173 (100.0)
Molecular subtype
Luminal A 21 (56.8) 121 (69.9)
Luminal B 9 (24.3) 28 (16.2)
HER2-overexpressed 1 (2.7) 11 (6.4)
Triple Negative 6 (16.2) 13 (7.5)
Total 37 (100.0) 173 (100.0)
**Significant differences at 95%.
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meeting point for a good sensitivity without unduly com-
promising specificity [25]. In addition, an increase in the
immediate recall rate involve a corresponding decrease in
the early-recall rate, and this may reduce pacient anxiety.
In the PEDBC the early recall rate has been decreased
until 0.6%.
Moreover the protocol classification or the experience
of radiologist expert panel could also influence the pro-
portion of false negative and dificult the comparision
with others programmes.
On the other hand, the proportional incidence in rela-
tion to incidence of breast cancer in the absence of
screning programme is an indicator that need to be eva-
luated in all programmes. In our study we found that in
the first year after screening mammography proportional
incidence is less than the 30% recommended by
European guidelines [6], and the same can be said of the
second year, with a proportional incidence of below 50%.
These results are better to those observed in other pro-
grammes [19,26,27]. However, differences in IC defi-
nition between studies have to be considered in the














Girona 54.5 13.6 13.6 18.2
Sabadell-Cerdanyola [15] 39.5 21.0 26.3 13.2
West Sussex [23] 54.3 33.6 - 12.1
Navarra [22] 57.7 12.3 15.0 15.0
Australia [20] 33.0 41.0 16.0 10.0
East Anglia [21] 66.2 17.2 5.4 11.3
Tarragona [25] 36.0 24.0 32.0 8.0
Barcelona [7] 52.3 20.0 6.2 21.5
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parameters. More in-depth classification of IC and its
determinants can contribute to adapting screening prac-
tices and improving their effectiveness. It is important
for radiologists to know what proportion of true IC, false
negatives, minimal signs and occult tumors are diag-
nosed in order to evaluate and improve their work.
One of the strengths of our study is the use of a
population-based registry that has collected data on can-
cer incidence in the province of Girona since 1980 [28].
Cross-referencing data from the target screening popula-
tion and all cases of breast cancer has allowed us to
identify all probable cases of IC.
However, we should take into account a number of
limitations when interpreting the results of our study: 1)
the heterogeneity of the different radiological units may
affect the ability to detect IC. 2) Partial recovery of the
mammograms needed for successful classification. In
our study we were only able to recover the two mammo-
grams (screening and diagnosis) necessary for the
correct classification of probable interval cancers in 50%
of cases as well as in other studies [15]. The main reason
for this was the difficulty to obtain the mammography at
the clinical record. As missing cases were randomly
distributed they probably does not introduce bias. 3)
Breast density is a well-known risk factor for breast
cancer and particulary interval cancer [29,30]. Unfortu-
nately, information on breast density is not avaible for
the study population.
When we compare our data with those reported in
other areas [15,19,22-24] it is noticeable that there is a
lower proportion of false negatives and a higher propor-
tion of occult tumors on the GHR program. However,
the small size of the series must be taken into account.
The comparitive analysis of clinicopathological vari-
ables between the IC and cancers diagnosed by screen-
ing (Table 4) suggests that IC are more aggressive
tumors and are associated with a worse prognosis. These
results are similar to those obtained previously in other
studies [7]. At the time of diagnosis, interval tumors
have a higher proportion of cases with advanced stages
and triple negatives. It is widely known that both aspects
are associated with a poor prognosis [31]. Tumor size is
greater in IC than in those detected by screening. This
supports the idea that IC tumors are more aggressive.
Also, it is found that most cancers detected by screening
are early stage tumors. This reinforces the idea that a
diagnostic advance is obtained with the PEDBC.
Conclusion
This study provides a major evaluation of the PEDBC.
Results show that the proportional incidence of IC, as
well as the percentage of false nevative IC of the PEDBC
is within the limits set by European guidelines. It isimportant for health professionals to know the true inci-
dence of IC and false negatives in order to improve
the effectiveness of the screening program. Further-
more, it has been confirmed that IC display more
aggressive clinicopathological characteristics than screen-
detected breast cancers.
Competing interests
Thex authors declare that they have no competing interests.
Authors’ contributions
RMG, MPV, MS and GRV made substancial contributions to conception and
design the study. MPV, JT, MC and GRV held data collection. JF, FC and JA
made the classification of inteval cancers. GRV performed the statistical
analysis. All authors helped to write the final manuscript and approved the
final version.
Acknowledgements
This study has been carried out with the financial support of the Carlos III
Health Institute, through two different grants PI09/90127 and RD12/0036/0056.
The authors wish to thank Laia Domingo for her contribution to the study
design, the centers that provided information and Rosa Massot for her extra
help.
Funding
Carlos III Health Institute, PI09/90127.
Author details
1Research Group on Statistics, Applied Economics and Health (GRECS), CIBER
of Epidemiology and Public Health (CIBERESP), University of Girona, Campus
de Montilivi, 17071 Girona, Spain. 2Epidemiology Unit and Girona
CancerRegistry (UERCG), Oncology Director Plan, Health Department, Girona,
Spain. 3Research Group on Statistics, Applied Economics and Health (GRECS),
CIBER of Epidemiology and Public Health (CIBERESP), Girona Biomedical
Research Institute (IdiBGi), Girona, Spain. 4Hospital Sta. Caterina, Salt, Spain.
5Institut d’Assistència Sanitaria, Girona, Spain. 6Hospital de Palamós, Palamos,
Spain. 7Servei d’Epidemiologia i Avaluació. Institut Hospital del Mar
d’Investigacions Mèdiques (IMIM), Barcelona Red de Investigación en
Servicios Sanitarios en enfermedades crónicas (REDISSEC), Barcelona, Spain.
8Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Director
Plan, Health Department, Girona Biomedical Research Institute (IdiBGi),
Girona, Spain.
Received: 3 February 2014 Accepted: 23 June 2014
Published: 1 August 2014
References
1. López-Abente G, Pollán M, Aragonés N, Pérez-Gómez B, Suárez B, Cárdaba
M, Cerdá T, Salas M: La situación del cáncer en España. Ministerio de Sanidad
y Consumo. Madrid: 2005. http://www.isciii.es/htdocs/centros/
epidemiologia/libros/cancermsc.pdf. Accessed 30/03/2011.
2. Sánchez MJ, Payer T, De Angelis R, Larrañaga N, Capocaccia R, Martinez C,
CIBERESP Working Group: Cancer incidence and mortality in Spain:
estimates and projections for the period 1981-2012. Ann Oncol 2010,
21(Suppl 3):iii30–iii36. doi:10.1093/annonc/mdq090.
3. Kaleger M, Zelen M, Langmark F, Adami H: Effect of screening
mammography on breast-cancer mortality in Norway. N Engl J Med 2010,
363:1203–1210. doi:10.1056/NEJMoa1000727.
4. Deck W, Kakuma R: Screening mammography: a reassessment. Agence
d'évaluation des technologies et des modes d'intervention en santé (AETMIS).
(AETMIS 05-03). AETMIS: Montréal; 2006.
5. Broeders M, Moss S, Nyström L, Nior S, Jonsson H, Paap E, Massat N, Duffy S,
Lynge E, Paci E, EUROSCREEN Working Group: The impact of
mammographic screening on breast cancer mortality in Europe:
a review of observational studies. J Med Screen 2012, 19(Suppl1):14–25.
6. Perry N, Broeders M, De Wolf C, Törnberg S, Holland R, von Karsa L:
European guidelines for quality assurance in breast cancer screening and
diagnosis. 4th edition. Luxembourg: Office for Official Publications of the
European Communities; 2006.
Renart-Vicens et al. BMC Cancer 2014, 14:558 Page 7 of 7
http://www.biomedcentral.com/1471-2407/14/5587. Domingo L, Sala M, Servitja S, Corominas J, Ferrer F, Martínez J, Macià F,
Quintana MJ, Albanell J, Castells X: Phenotypic characterization and risk
factors for interval breast cancers in a population-based breast cancer
screening program in Barcelona, Spain. Cancer Causes Control 2010,
21(8):1155–1164. doi:10.1007/s10552-010-9541-6.
8. Rayson D, Payne JI, Abdolell M, Barnes PJ, Macintosh RF, Foley T, Younis T,
Burns A, Caines J: Comparison of clinical-pathologic characteristics and
outcomes of true interval and screen-detected invasive breast cancer
among participants of a Canadian breast screening program: a nested
case-control study. Clin Breast Cancer 2011, 11:27–32.
9. Kirsh VA, Chiarelli AM, Edwards SA, O’Malley FP, Shumak RS, Yaffe MJ Boyd
NF: Tumor characteristics associated with mammographic detection of
breast cancer in the Ontario breast screening program. J Natl Cancer Inst
2011, 103(12):942–950. doi:10.1093/jnci/djr138.
10. Fracheboud J, de Koning HJ, Beemsterboer PM, Boer R, Verbeek ALM,
Hendriks JHCL, van Ineveld BM: Interval cancers in the Dutch breast
cancer screening programme. Br J Cancer 1999, 81(5):912–917.
doi:10.1038/sj.bjc.6690786.
11. Warren R, Duffy S: Interval cancers as an indicator of performance in
breast screening. Breast Cancer 2000, 7(1):9–18.
12. Ganry OF, Peng J, Raverdy NL, Dubreuil AR: Interval cancers in a French
breast cancer-screening programme (Somme Department). Eur J Cancer
Prev 2001, 10(3):269–274.
13. Hofvind S, Bjurstam N, Sorum R, Biorndal H, Thoresen S, Skaane P: Number
and characteristics of breast cancer cases diagnosed in four periods in
the screening interval of a biennial population-based screening
programme. J Med Screen 2006, 13(4):192–196.
14. Michelena M: Tumores de intervalo en el programa de detecciónprecoz
del cáncer de mama. In Imaña J, Izarzugaza I, Pericás I, Rueda JR, Sarriugarte
G (editores). Informe de evaluación. Gobierno Vasco: Departamento de
Sanidad; 2007.
15. Bare M, Sentís M, Galceran J, Ameijide A, Andreu X, Ganau S, Tortajada L,
Planas J: Breast Cancer Screening Programme (BCSP) of Sabadell
Cerdanyola Research Group on Interval Cancers: Interval breast cancers
in a community screening programme: frequency, radiological
classification and prognostic factors. Eur J Cancer Prev 2008, 17(5):414–421.
16. Bucchi L, Ravaioli A, Foca F, Colamartini A, Falcini F, Naldoni C, Emilia-
Romaqna Breast Screening Programme: Incidence of interval breast
cancers after 650,000 negative mammographies in 13 Italian health
districts. J Med Screen 2008, 15(1):30–35. doi:10.1258/jms.2008.007016.
17. World Health Organization: International Statistical Classification of Disease
and Related Health Problems, 10th revision. Geneva: World health
Organization; 2003.
18. Sobin LH, Wittekind C, editores: TNM classification of malignant tumours:
International Union Against Cancer. 6th edition. New York: John Wiley &
Sons; 2002.
19. Raja MAK, Hubbard A, Salman AR: Interval breast cancer: is it a different
type of breast cancer? Breast 2001, 10(2):100–108.
20. Galceran J, Saladie F and PRENEMACT research group: Interval cancers of the
Tarragona Breast Cancer Screening Programme. Terres de l’Ebre: Programa de
detección precoz del càncer de mama de Tarragona; 2004.
21. Vitak B: Invasive interval cancers in the Ostergotland mammographic
Screening Programme: radiological analysis. Eur Radiol 1998, 8:639–646.
22. Amos AF, Kavanagh AM, Cawson J: and the Radiology Quality Assurance
Group of Breast Screen Victoria. Radiological review of interval cancers
in an Australian Mammographic screening programe. J Med Screen 2000,
7:184–189. doi:10.1136/jms.7.4.184.
23. McCann J, Britton PD, Warren RML, Unam G, Behalf of the East Anglian
Breast Screening Programme: Radiological peer review of interval cancers
in the East Anglian breast screening programme: what are we missing?
J Med Screen 2001, 8:77–85. doi:10.1136/jms.8.2.77.
24. Mellado M, Murillo A, Osa A, Barcos A, Apesteguía L, Martínez-Peñuela JM:
Cáncer de intervalo. Experiencia en el Programa de Prevención de Cáncer
de Mama de Navarra (1990-2000). Radiologia 2004, 46(5):314–319. 46.
25. Apesteguía L, Pina LJ: Population-based breast cancer screening:
Certainties, controversies, and future perspectives. Radiologia 2014.
In press.
26. Wang H, Bjurstam N, Bjorndal H, Braaten A, Eriksen L, Skaane P, Vitak B,
Hofvind S, Thoresen SO: Interval cancers in the Norwegian breast cancer
screening program: frequancy, characteristics and use of HRT. Int J
Cancer 2001, 94:594–598.27. Taylor R, Supramaniam R, Rickard M, Estoesta J, Moreira C: Interval breast
cancers in New South Wales, Australia, and comparisons with trials and
other mammographic screening programmes. J Med Screen 2002,
9:20–25.
28. Viladiu P, Izquierdo A, Beltrán M, Bosch FX, Moreno V: Epidemiologia del
càncer ginecològic i de mama a l’àrea sanitària de Girona. AECC: Registre del
Càncer de Girona; 1996.
29. Mandelson MT, Oestreicher N, Poter PL, White D, Finder CA, Taplin SH,
White E: Breast density as a predictor of mammographic detection:
comparision of interval-and screen-detected cancers. J Natl Cancer Inst
2000, 92:1081–1087.
30. Pollan M, Ascunce N, Ederra M, Murillo A, Erdozain N, Ales-Martinez JE,
Pastor-Barriuso R: Mammographic density and risk of breast cancer
according to tumor characteristics and mode of detection: a Spanish
population-based case-control study. Breast Cancer Res 2013, 15:R9.
31. Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda
A, Redondo M, Castells X, Sala M: Aggressiveness features and outcomes
of true interval cancers: comparison between screen-detected and
symptom-detected cancers. Eur J Cancer Prev 2013. doi:10.1097/
CEJ.0b013e328354d324.
doi:10.1186/1471-2407-14-558
Cite this article as: Renart-Vicens et al.: Evaluation of the interval cancer
rate and its determinants on the Girona health region’s early breast
cancer detection program. BMC Cancer 2014 14:558.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
